Staging HPV-related oropharyngeal cancer: Validation of AJCC-8 in a surgical cohort
Daniel Clayburgh(Oregon Health & Science University), Brennan Olson(Mayo Clinic), Michael J. Persky(New York University), Marnie Bertolet(University of Pittsburgh), William G. Albergotti(University of Pittsburgh Medical Center), Umamaheswar Duvvuri(City University of New York), John P. Gleysteen(University of Tennessee Health Science Center), Neil D. Gross(The University of Texas MD Anderson Cancer Center), Robert L. Ferris(University of Pittsburgh), Seungwon Kim(UPMC Hillman Cancer Center), Ryan Li, Peter E. Andersen(Oregon Health & Science University)
Cited by 30
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression
|Oral Oncology|2018|802
Immune Landscape of Viral- and Carcinogen-Driven Head and Neck Cancer
|Immunity|2020|688
Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial
|The Lancet Oncology|2021|618
Frequent Mutation of the PI3K Pathway in Head and Neck Cancer Defines Predictive Biomarkers
|Cancer Discovery|2013|590